Community pharmacist intervention in depressed primary care patients (PRODEFAR study): Randomized controlled trial protocol

BMC Public Health

Volumn 9, Issue , 2009, Pages

  Rubio Valera, Maria ^a,b   Serrano Blanco, Antoni ^a,b   Travé, Pere ^c,d   Pẽarrubia María, M Teresa ^b,e   Ruiz, Mar ^a   Pujol, Marian March ^c  

^a HOSPITAL CLÍNIC   (Spain)

^b Red de Investigacion en Actividades Preventivas y Promocion de la Salud en Atencion Primaria RedIAPP   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d ABS Just Oliveres   (Spain)

^e INSTITUT CATALÀ DE LA SALUT   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

ABDOMINAL CRAMP; ADULT; AGED; ANXIETY; ARTICLE; ASTHENIA; AWARENESS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG INDUCED HEADACHE; DRUG INFORMATION; FATIGUE; FOLLOW UP; HEART PALPITATION; HUMAN; KNOWLEDGE; LASSITUDE; LIBIDO; MAJOR CLINICAL STUDY; MENTAL HEALTH SERVICE; MENTAL PATIENT; NAUSEA AND VOMITING; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHARMACEUTICAL CARE; PRIMARY MEDICAL CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SALIVATION DISORDER; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SPAIN; STIGMA; SWEATING; TACHYCARDIA; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN; WEIGHT REDUCTION; ADOLESCENT; COST BENEFIT ANALYSIS; MIDDLE AGED; PHARMACIST; PHARMACY; PRIMARY HEALTH CARE;

ADOLESCENT; ADULT; AGED; COST-BENEFIT ANALYSIS; DEPRESSION; HUMANS; MIDDLE AGED; PHARMACIES; PHARMACISTS; PRIMARY HEALTH CARE; QUALITY OF LIFE; YOUNG ADULT;

EID: 69449098803     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-9-284     Document Type: Article

References (43)

1. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. K Demyttenaere R Bruffaerts J Posada-Villa I Gasquet V Kovess JP Lepine MC Angermeyer S Bernert G De Girolamo P Morosini G Polidori T Kikkawa N Kawakami Y Ono T Takeshima H Uda EG Karam JA Fayyad AN Karam ZN Mneimneh ME Medina-Mora G Borges C Lara R De Graaf J Ormel O Gureje Y Shen Y Huang M Zhang J Alonso JM Haro G Vilagut EJ Bromet S Gluzman C Webb RC Kessler KR Merikangas JC Anthony MR Von Korff PS Wang TS Brugha S Aguilar-Gaxiola S Lee S Heeringa BE Pennell AM Zaslavsky TB Ustun S Chatterji, JAMA 2004 291 2581 2590
2. Prevalence of mental disorders in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. J Alonso MC Angermeyer S Bernert R Bruffaerts TS Brugha H Bryson G De Girolamo R Graaf K Demyttenaere I Gasquet JM Haro SJ Katz RC Kessler V Kovess JP Lepine J Ormel G Polidori LJ Russo G Vilagut J Almansa S Arbabzadeh-Bouchez J Autonell M Bernal MA Buist-Bouwman M Codony A Domingo-Salvany M Ferrer SS Joo M Martinez-Alonso H Matschinger F Mazzi Z Morgan P Morosini C Palacin B Romera N Taub WA Vollebergh, Acta Psychiatr Scand Suppl 2004 420 21 27
3. Epidemiology of major depressive episode in a southern European country: Results from the ESEMED-Spain project. A Gabilondo S Rojas-Farreras G Vilagut JM Haro A Fernández A Pinto-Meza J Alonso, J Affect Disord 2009
4. A Serrano-Blanco DJ Palao JV Luciano A Pinto-Meza L Luján A Fernandez J Bertsch M Mercader JM Haro, Soc Psychiatry Psychiatr Epidemiol 2009
5. Projections of global mortality and burden of disease from 2002 to 2030. CD Mathers D Loncar, PLoS Med 2006 3 e442
6. Disability and quality of life impact of mental disorders in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. J Alonso MC Angermeyer S Bernert R Bruffaerts TS Brugha H Bryson G De Girolamo R Graaf K Demyttenaere I Gasquet JM Haro SJ Katz RC Kessler V Kovess JP Lepine J Ormel G Polidori LJ Russo G Vilagut J Almansa S Arbabzadeh-Bouchez J Autonell M Bernal MA Buist-Bouwman M Codony A Domingo-Salvany M Ferrer SS Joo M Martinez-Alonso H Matschinger F Mazzi Z Morgan P Morosini C Palacin B Romera N Taub WA Vollebergh, Acta Psychiatr Scand Suppl 2004 420 38 46
7. [The impact of mood and anxiety disorders, and physical chronic conditions in the quality of life of general population of Spain. Results of the ESEMeD-Spain study]. A Pinto-Meza JM Haro C Palacin JV Torres S Ochoa G Vilagut M Martinez-Alonso M Codony J Alonso, Actas Esp Psiquiatr 2007 35 Suppl 2 12 20
8. Cost of depression in Europe. P Sobocki B Jonsson J Angst C Rehnberg, J Ment Health Policy Econ 2006 9 87 98
9. Adequacy of antidepressant treatment in Spanish primary care: a naturalistic six-month follow-up study. A Pinto-Meza A Fernandez A Serrano-Blanco JM Haro, Psychiatr Serv 2008 59 78 83
10. Treatment non-adherence in affective disorders. R Lingam J Scott, Acta Psychiatr Scand 2002 105 164 172
11. World Health Organization (WHO), The role of the pharmacist in the health care system. Geneva 1994 http://apps.who.int/medicinedocs/es/d/Jh2995e/
12. Council of Europe, Committee of Ministers, Resolution ResAP (2001) concerning the pharmacist's role in the framework of health security. Adopted by the Committee of Ministers at the 76th meeting of the Ministers' Deputies 2001 https://wcd.coe.int/ViewDoc.jsp?id=193721&BackColorInternet= 9999CC&BackColorIntranet=FFBB55&BackColorLogged=FFAC75
13. World Health Organization (WHO), Improving access and use of psychotropic medicines. Geneva 2004 http://whqlibdoc.who.int/publications/2004/9241546417. pdf
14. Sensitivity of patient outcomes to pharmacist interventions. Part I: systematic review and meta-analysis in diabetes management. M Machado J Bajcar GC Guzzo TR Einarson, Ann Pharmacother 2007 41 1569 1582 (Pubitemid 47479786)
15. Sensitivity of patient outcomes to pharmacist interventions. Part II: systematic review and meta-analysis in hypertension management. M Machado J Bajcar GC Guzzo TR Einarson, Ann Pharmacother 2007 41 1770 1781 (Pubitemid 350044338)
16. A pharmacy-based coaching program to improve adherence to antidepressant treatment among primary care patients. OH Brook H van Hout W Stalman H Nieuwenhuyse B Bakker E Heerdink M de Haan, Psychiatr Serv 2005 56 487 489
17. Improving patient feedback about and outcomes with antidepressant treatment: a study in eight community pharmacies. NM Rickles BL Svarstad JL Statz-Paynter LV Taylor KA Kobak, J Am Pharm Assoc (2003) 2006 46 25 32
18. Patient outcomes following an intervention involving community pharmacists in the management of depression. J Crockett S Taylor A Grabham P Stanford, Aust J Rural Health 2006 14 263 269
19. Randomized trial of pharmacist interventions to improve depression care and outcomes in primary care. KL Capoccia DM Boudreau DK Blough AJ Ellsworth DR Clark NG Stevens WJ Katon SD Sullivan, Am J Health Syst Pharm 2004 61 364 372
20. Impact of a collaborative pharmacy practice model on the treatment of depression in primary care. PR Finley HR Rens JT Pont SL Gess C Louie SA Bull LA Bero, Am J Health Syst Pharm 2002 59 1518 1526
21. The impact of a pharmacist intervention on 6-month outcomes in depressed primary care patients. DA Adler KM Bungay IB Wilson Y Pei S Supran E Peckham DJ Cynn WH Rogers, Gen Hosp Psychiatry 2004 26 199 209 (Pubitemid 38581925)
22. Cost effectiveness of a pharmacy-based coaching programme to improve adherence to antidepressants. JE Bosmans OH Brook HP Van Hout MC de Bruijne H Nieuwenhuyse LM Bouter WA Stalman MW van Tulder, Pharmacoeconomics 2007 25 25 37
23. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. DG Altman KF Schulz D Moher M Egger F Davidoff D Elbourne PC Gøtzsche T Lang, Ann Intern Med 2001 134 663 694 (Pubitemid 32322245)
24. MB First RL Spitzer M Gibbon JB William, Structured Clinical Interview Axis I DSM-IV Disorders, Research Version (SCID-RV) American Psychiatric Press, Inc, Washington 1996
25. MB First RL Spitzer M Gibbon JB William, Entrevista clínica estructurada para los trastornos del eje I del DSM-IV. Barcelona, Spain, Masson, 1999
26. Concurrent and predictive validity of a self-reported measure of medication adherence. DE Morisky LW Green DM Levine, Med Care 1986 24 67 74
27. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. RL Spitzer K Kroenke JB Williams, JAMA 1999 282 1737 1744
28. The PHQ-9: validity of a brief depression severity measure. K Kroenke RL Spitzer JB Williams, J Gen Intern Med 2001 16 606 613
29. Validation and utility of the patient health questionnaire in diagnosing mental disorders in 1003 general hospital Spanish inpatients. C Diez-Quevedo T Rangil L Sanchez-Planell K Kroenke RL Spitzer, Psychosom Med 2001 63 679 686
30. [One year prevalence of mental disorders comorbidity and associated socio-demographic risk factors in the general population of Spain. Results of the ESEMeD-Spain study]. J Autonell F Vila A Pinto-Meza G Vilagut M Codony J Almansa PE Mũoz JV Torres J Alonso JM Haro, Actas Esp Psiquiatr 2007 35 Suppl 2 4 11
31. CD Spielberger RL Gorsuch RD Lushene, Manual for the State-Trait Anxiety Inventory Palo Alto, CA: Consulting Psychological Press 1970
32. CD Spielberger RL Gorsuch RE Lushene, Cuestionario de Ansiedad Estado-Rasgo TEA Ediciones, Madrid 2 1986
33. EuroQol a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990 16 199 208
34. Using the EuroQol 5-D in the Catalan general population: feasibility and construct validity. X Badia A Schiaffino J Alonso M Herdman, Qual Life Res 1998 7 311 322
35. [The Spanish version of EuroQol: a description and its applications. European Quality of Life scale]. X Badia M Roset S Montserrat M Herdman A Segura, Med Clin (Barc) 1999 112 Suppl 1 79 85
36. A social tariff for EuroQol: Results from a UK general population survey. P Dolan C Gudex P Kind A Williams, University of York: Centre for Health Economics 1995 Discussion Paper 138
37. Development and validation of a Spanish language patient satisfaction questionnaire with drug dispensing. PD Armando P Martinez Sr PM Marti NH Sola Uthurry MJ Faus Dader, Pharm World Sci 2008 30 169 174
38. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. O Lingjaerde UG Ahlfors P Bech SJ Dencker K Elgen, Acta Psychiatr Scand Suppl 1987 334 1 100
39. World Health Organization (WHO), Innovative care for chronic conditions: Building blocks for action. Geneva 2002
40. M Knapp (PSSRU and Centre for Economics of Mental Health, Institute of Psychiatry, University of Kent), Economic evaluation of Mental Health Care Ashgate Publishing Group 1995
41. Unit cost Database. http://www.oblikue.com/
42. MF Drummond MJ Sculpher GW Torrance BJ O'Brien GL Stoddart, Methods for the Economic Evaluation of Health Care Programmes New York: Oxford University Press Third 2005
43. B Efron RJ Tibshirani, An introduction to the bootstrap Florida: Chapman and Hall/CRC 2 1998